Connecticut Clinical Trials Report — April 2026

For Connecticut residents considering participation in clinical trials, April 2026 presents a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 91 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 16 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Obesity
• Stage IV lung cancer AJCC V8
• Type 2 diabetes
• Infertility
• Deep venous thrombosis
• Irritable bowel syndrome with constipation (IBS-C)
• Advanced solid tumor
• Cannabis use
• Advanced breast cancer

Groundbreaking Research Launches: Obesity, Liver Health, and Pain Management

This month brings several high-profile new trials to Connecticut, including significant Phase 2 and 3 studies from major pharmaceutical companies and federal institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to chronic pain.

A standout new opportunity comes from Novo Nordisk A/S, a leading pharmaceutical sponsor. Their Phase 3 study, NCT07509307, titled "AMAZE 6," is investigating a new medicine, NNC0487-0111, for individuals with excess body weight and knee osteoarthritis. This large trial aims to enroll 400 participants to evaluate the safety and effect of this weekly injectable treatment compared to a placebo, offering a potential new approach for managing both weight and joint pain.

Another notable study is sponsored by the VA Office of Research and Development. NCT07528690, "Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)," is a Phase 2 trial. It seeks to understand if changing gut microbes using capsules from healthy individuals can prevent future episodes of hepatic encephalopathy in Veterans with cirrhosis. This innovative approach could significantly improve the quality of life for those affected by severe liver conditions.

For individuals experiencing knee pain, ZetrOZ, Inc. is sponsoring NCT07515872, a Phase 2 study. This trial is assessing the ability of long-duration high-frequency continuous-wave therapeutic ultrasound to alleviate knee osteoarthritis pain over an 12-week period, offering a non-pharmacological treatment option.

Yale University continues to be a significant contributor to the state's research landscape, sponsoring 5 of the new trials this month. Their studies include:

• NCT07519733: "Preoperative Exercise Testing and Perioperative Outcomes." This observational study, involving 992 participants, aims to identify adults over 45 years who may be more likely to experience problems after moderate- to high-risk noncardiac surgery based on a brief exercise test.
• NCT07515846: "Breast Cancer Screening Decision Aid." This randomized survey study with 300 participants compares a video-based decision aid to a written one for breast cancer screening, assessing their impact on patient understanding and choices.

April's Research Landscape: New Opportunities and Geographic Reach

This month, Connecticut saw the opening of 9 new clinical trials, a decrease from the 13 trials that launched in March 2026. Despite this modest dip, the state continues to offer a diverse array of research opportunities, with a total of 1,243 clinical trials currently recruiting across 53 cities and 625 research sites.

The majority of new research initiatives this month are concentrated in key urban centers. New Haven leads with 6 new trials, reflecting its status as a major research hub. Other cities with new trial openings include:

• Stamford (1 new trial)
• Waterbury (1 new trial)
• West Haven (1 new trial)

While new trial openings are centralized, the overall research landscape remains broadly accessible across Connecticut, with active research sites spanning a wide geographic area.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Alcohol use disorder
• Arthritis
• Cirrhosis
• Decision aid
• Geriatrics
• Hepatic encephalopathy
• Mammography screening
• Membrane potential mapping
• Obesity
• Osteoarthritis of the knee

The types of interventions being studied are varied, with drug trials leading the way, accounting for 4 of the new trials. Behavioral interventions represent 3 new trials, while biological, device, diagnostic test, and other types of studies each account for 1 new trial.

Who Can Participate? Healthy Volunteers and Diverse Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 9 new trials launched this month, 8 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. One new trial is specifically designed for female participants. There are no new trials this month that include children.

For individuals without a specific medical condition, there are significant opportunities to contribute. 5 of the new trials this month are actively seeking healthy volunteers. Across Connecticut, a total of 154 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions, particularly Yale University, continue to play a vital role in Connecticut's research ecosystem, sponsoring 5 of the new trials. Industry sponsors, including Novo Nordisk A/S, Newleos Therapeutics, Inc., and ZetrOZ, Inc., are also driving significant research efforts, accounting for 3 of the new studies this month. Additionally, the VA Office of Research and Development contributes with 1 new federally sponsored trial.

As we move further into spring, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Connecticut.